OncoHost announced a research study with Dana-Farber Cancer Institute to identify biomarkers for renal cell carcinoma (RCC), a type of kidney cancer.
Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients.
The collaboration will leverage Dana-Farber's repository of patient plasma samples and corresponding clinical data, providing essential materials for OncoHost to create a proteomic plasma profile.
The primary objectives of the study include creating a proteomic plasma profile of metastatic RCC patients before treatment, thereby associating protein expression changes with treatment response metrics like Best Response, Overall Survival, and Progression-Free Survival, and evaluating differential response predictions to specific treatment combinations.
The research project will also explore proteomic pathways associated with treatment response and immune-related adverse events (irAEs), offering potential insights into treatment options and biological patterns of resistance. Comparisons with pathways identified in other cancers, as part of the PROPHETIC trial (NCT04056247), will further enhance the understanding of RCC's unique biomolecular landscape.
